Review
Pharmacology & Pharmacy
Marcella Liciani Franco, Stephany Beyerstedt, erika Bevilaqua Rangel
Summary: Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems associated with comorbidities such as diabetes mellitus and hypertension. Klotho has shown promising potential as a therapeutic approach for these kidney conditions. It exerts renoprotective effects by reducing inflammation, oxidative stress, and fibrosis. Mesenchymal stem cells (MSCs) are an important strategy for delivering Klotho.
Review
Cell & Tissue Engineering
Ria Margiana, Alexander Markov, Angelina O. Zekiy, Mohammed Ubaid Hamza, Khalid A. Al-Dabbagh, Sura Hasan Al-Zubaidi, Noora M. Hameed, Irshad Ahmad, R. Sivaraman, Hamzah H. Kzar, Moaed E. Al-Gazally, Yasser Fakri Mustafa, Homayoon Siahmansouri
Summary: MSCs have great potential for immunomodulation and tissue regeneration, and can be used for the treatment of various diseases. Recent advances in MSCs biology have facilitated their clinical application.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Cell Biology
Yuexin Zhu, Manyu Luo, Xue Bai, Yan Lou, Ping Nie, Shan Jiang, Jicui Li, Bing Li, Ping Luo
Summary: Diabetic kidney disease is a serious complication of diabetes, and there are currently no effective drugs to prevent its progression. Mesenchymal stem cells have shown promise as a new treatment option for diabetic kidney disease, but their exact role and mechanism of action remain unclear.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Hua-Min Zhang, Shuo Yuan, Huan Meng, Xiao-Ting Hou, Jiao Li, Jia-Chen Xue, You Li, Qi Wang, Ji-Xing Nan, Xue-Jun Jin, Qing-Gao Zhang
Summary: Inflammatory bowel disease (IBD) is a chronic, relapsing disease that greatly affects patients' quality of life. Stem cell therapy has shown potential to improve the clinical disease activity of patients with refractory IBD when conventional treatments are not effective, but its safety and long-term efficacy need further evaluation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Qinghua Cao, Chunling Huang, Xin-Ming Chen, Carol A. Pollock
Summary: Chronic kidney disease (CKD) is a global public health problem with increasing prevalence worldwide. Current treatments are limited, and innovative strategies for kidney tissue recovery show promise. Mesenchymal stem cells (MSCs) release extracellular vesicles (MSC-Exos) that deliver various substances to target cells. MSC-Exos as a cell-free therapy have emerged as a potential treatment for CKD.
FRONTIERS IN MEDICINE
(2022)
Review
Polymer Science
Cecilie Hoeeg, Alireza Dolatshahi-Pirouz, Bjarke Follin
Summary: Cell therapy has the potential to regenerate cardiac tissue and treat various cardiac diseases. Injectable hydrogels have been investigated for their potential to improve cell graft retention and enhance the effects of cardiac cell therapy.
Article
Biochemistry & Molecular Biology
Mohammad Mousaei Ghasroldasht, Jin Seok, Hang-Soo Park, Farzana Begum Liakath Ali, Ayman Al-Hendy
Summary: Regenerative medicine is a promising therapeutic mode using stem cells for the treatment of challenging human diseases. Stem cells have pleotropic therapeutic potential through inflammation or apoptosis inhibition, cell recruitment, angiogenesis stimulation, and differentiation. This review provides an overview of the translation process from idea to clinical practice, including guidelines for clinical trial approval and a review of regenerative medicine clinical trials registered on the Clinicaltrials.gov website.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Dentistry, Oral Surgery & Medicine
Liang Sun, Xinya Du, Huifang Kuang, Honglan Sun, Wen Luo, Chao Yang
Summary: Periodontitis is a common and chronic inflammatory disease that leads to tooth loss. Stem cell-based therapy has been used in the clinic but its effectiveness in periodontal regeneration is still uncertain.
Review
Cell & Tissue Engineering
Ying Li, Jie Hao, Zheng Hu, Yong-Guang Yang, Qi Zhou, Liguang Sun, Jun Wu
Summary: This study summarized 79 clinical trials involving the use of MSCs to prevent or treat GVHD, analyzing their characteristics and results. The researchers aimed to gain a comprehensive understanding of the progress, challenges, limitations, and future trends in the field, and provide new perspectives for the design of future trials.
STEM CELL RESEARCH & THERAPY
(2022)
Review
Cell Biology
Trinidad Montero-Vilchez, Alvaro Sierra-Sanchez, Manuel Sanchez-Diaz, Maria Isabel Quinones-Vico, Raquel Sanabria-de-la-Torre, Antonio Martinez-Lopez, Salvador Arias-Santiago
Summary: Mesenchymal stromal cell-conditioned medium (MSC-CM) shows promising potential in treating skin conditions by improving wound healing, hair restoration, skin rejuvenation, and some inflammatory skin diseases. Further research is needed to confirm its safety, effectiveness, and to standardize the manufacturing process.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Bernard J. Smilde, Esmee Botman, Teun J. de Vries, Ralph de Vries, Dimitra Micha, Ton Schoenmaker, Jeroen J. W. M. Janssen, Elisabeth M. W. Eekhoff
Summary: Fibroblasts play a crucial role in maintaining the extracellular matrix of connective tissues. Recent studies have found donor-derived fibroblasts in bone marrow transplant recipients, though some findings were not replicated. This systematic review provides an overview of hematopoietic stem cells differentiating into fibroblasts in various tissues, revealing evidence of fibroblasts derived from hematopoietic stem cells in almost all organs.
Review
Cardiac & Cardiovascular Systems
Carlos Theodore Huerta, Francesca A. Voza, Yulexi Y. Ortiz, Zhao-Jun Liu, Omaida C. Velazquez
Summary: Progressive peripheral arterial disease (PAD) can lead to chronic limb-threatening ischemia (CLTI), resulting in non-healing wounds and tissue loss. Current therapies for CLTI, such as revascularization and medical management, have limitations, and regenerative therapies utilizing mesenchymal stem/stromal cells (MSCs) hold promise in improving wound healing and limb salvage. In this review, we focus on the specific effects of MSC-based therapeutics on ischemic non-healing wounds associated with CLTI, providing insights from pre-clinical and clinical studies.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Review
Cell & Tissue Engineering
LaTonya J. Hickson, Tala Abedalqader, Gift Ben-Bernard, Jayla M. Mondy, Xiaohui Bian, Sabena M. Conley, Xiangyang Zhu, Sandra M. Herrmann, Aleksandra Kukla, Elizabeth C. Lorenz, Seo Rin Kim, Bjorg Thorsteinsdottir, Lilach O. Lerman, M. Hassan Murad
Summary: Cell-based interventions showed significant improvement in kidney function and reduction in injury in diabetic animal models of kidney disease. Treatment-related factors, such as cell type, tissue source, cell dose, and administration route, played a role in modifying treatment effects.
STEM CELLS TRANSLATIONAL MEDICINE
(2021)
Review
Cell Biology
Yelei Cen, Guohua Lou, Jinjin Qi, Min Zheng, Yanning Liu
Summary: Mesenchymal stem cells (MSCs) show promise as an alternative treatment for liver disease due to their ability to regenerate, inhibit fibrosis, and regulate the immune system. Impaired mitochondrial function is a common feature in liver diseases, leading to ATP synthesis dysfunction, decreased respiratory chain activity, and altered mitochondrial dynamics. Recent evidence suggests that MSCs can not only replace damaged cells and have paracrine effects, but also regulate mitochondrial dysfunction in liver disease. This review comprehensively discusses the role of mitochondrial dysfunction in liver disease and how MSCs can target it, as well as recent advances in modifying MSCs to enhance their functions in treating liver disease.
CELL COMMUNICATION AND SIGNALING
(2023)
Review
Biochemistry & Molecular Biology
Pei-Wen Lee, Bo-Sheng Wu, Chih-Yu Yang, Oscar Kuang-Sheng Lee
Summary: Mesenchymal stem cells (MSCs) and MSC-derived EVs are considered promising cellular therapies for treating AKI, as they benefit kidney regeneration by releasing paracrine factors and extracellular vesicles. Research aims to deepen the understanding of molecular signaling and cellular communication between donor MSCs and recipient kidney cells, in order to develop more effective therapies for AKI.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Viviana Palazzo, Valentina Raglianti, Samuela Landini, Luigi Cirillo, Carmela Errichiello, Elisa Buti, Rosangela Artuso, Lucia Tiberi, Debora Vergani, Elia Dirupo, Paola Romagnani, Benedetta Mazzinghi, Francesca Becherucci
Summary: This study assessed the diagnostic rate of whole-exome sequencing (WES) in Bartter and Gitelman syndromes and explored genotype-phenotype correlations. The findings improve the understanding of differential diagnosis and genotype-phenotype correlation in these disorders.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Letizia De Chiara, Gianmarco Lugli, Gianluca Villa, Valentina Raglianti, Faeq Husain-Syed, Fiammetta Ravaglia, Paola Romagnani, Elena Lazzeri
Summary: This review discusses the mechanisms of chemotherapy-induced acute kidney injury, available biomarkers for early detection, and raises awareness of chemotherapy-induced acute kidney injury.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Urology & Nephrology
Lorenzo Lodi, Maria V. Mastrolia, Federica Bello, Giovanni M. Rossi, Maria L. Angelotti, Yanick J. Crow, Paola Romagnani, Augusto Vaglio
Summary: Type I interferon mediates tissue damage in kidney disorders, affecting the function of various renal cell types. These disorders can cause renal dysfunction and share pathological features. Defining the classification, pathogenic mechanisms, and histopathological patterns of IFN-I-related kidney disorders is crucial for diagnosis and treatment.
KIDNEY INTERNATIONAL
(2022)
Review
Pediatrics
Luigi Cirillo, Fiammetta Ravaglia, Carmela Errichiello, Hans-Joachim Anders, Paola Romagnani, Francesca Becherucci
Summary: Chronic kidney disease (CKD) is a global public healthcare concern in the pediatric population, with glomerulopathies being the second most common cause. Sodium-glucose transporter 2 inhibitors (SGLT2i) show promise in slowing the progression of CKD and glomerular diseases in children, although their use in this population is not yet approved.
PEDIATRIC NEPHROLOGY
(2022)
Letter
Immunology
Luigi Cirillo, Francesco Citera, Tommaso Mazzierli, Francesca Becherucci, Vito Terlizzi, Lorenzo Lodi, Elisa Buti, Paola Romagnani
Review
Cell Biology
Fiammetta Ravaglia, Maria Elena Melica, Maria Lucia Angelotti, Letizia De Chiara, Paola Romagnani, Laura Lasagni
Summary: Podocytopathies are a group of proteinuric glomerular disorders driven by primary podocyte injury, with various lesion patterns observed on kidney biopsy. Recent evidence suggests that these patterns represent signs of repeated injury and repair attempts, depending on the type, length, and severity of the podocyte injury, as well as the ability of parietal epithelial cells to drive repair processes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Urology & Nephrology
Giorgio Trivioli, Elena Gelain, Maria L. Angelotti, Fiammetta Ravaglia, Marco Allinovi, Lorenzo Lodi, Leonardo Caroti, Annamaria Buccoliero, Giacomo Emmi, Marco Gattorno, Paola Romagnani, Stefano Volpi, Augusto Vaglio
Summary: ADA2 deficiency is a rare genetic disease that can cause various kidney manifestations and may be associated with type I interferon.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Article
Immunology
Maud Tusseau, Ema Lovsin, Charlotte Samaille, Remi Pescarmona, Anne-Laure Mathieu, Maria-Cristina Maggio, Velma Selmanovic, Marusa Debeljak, Angelique Dachy, Gregor Novljan, Alexandre Janin, Louis Januel, Jean-Baptiste Gibier, Emilie Chopin, Isabelle Rouvet, David Goncalves, Nicole Fabien, Gillian Rice, Gaetan Lesca, Audrey Labalme, Paola Romagnani, Thierry Walzer, Sebastien Viel, Magali Perret, Yanick J. Crow, Tadej Avcin, Rolando Cimaz, Alexandre Belot
Summary: The interferon signaling in DNASE1L3 deficient patients is transient, unlike the anomalies observed in other diseases. DNASE1L3 deficiencies are associated with a broad phenotype including lupus nephritis and hypocomplementemic urticarial vasculitis.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Cell Biology
Maria Elena Melica, Giulia Antonelli, Roberto Semeraro, Maria Lucia Angelotti, Gianmarco Lugli, Samuela Landini, Fiammetta Ravaglia, Gilda La Regina, Carolina Conte, Letizia De Chiara, Anna Julie Peired, Benedetta Mazzinghi, Marta Donati, Alice Molli, Stefanie Steiger, Alberto Magi, Niccolo Bartalucci, Valentina Raglianti, Francesco Guzzi, Laura Maggi, Francesco Annunziato, Alexa Burger, Elena Lazzeri, Hans-Joachim Anders, Laura Lasagni, Paola Romagnani
Summary: Crescentic glomerulonephritis is a disease characterized by vascular necrosis and hyperplasia of epithelial cells, resulting in the formation of crescents. Little is known about the molecular mechanisms driving this process. Research on mouse models showed that crescents are derived from the clonal expansion of immature parietal epithelial cells. Treatment with panobinostat, a histone deacetylase inhibitor, attenuated crescentic glomerulonephritis and restored kidney function by inducing differentiation of immature hyperplastic parietal epithelial cells into podocytes.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Transplantation
Lyuben Lyubenov, Chongxu Shi, Danyang Zhao, Luying Yang, Yutian Lei, Elmina Mammadova-Bach, Letizia de Chiara, Roberto Semeraro, Samuela Landini, Paola Romagnani, Elena Voerg, Satish K. Devarapu, Ricarda Welz, Stephan T. Kiessig, Hans-Joachim Anders
Summary: Cholesterol crystal (CC) embolism leads to acute kidney injury (AKI) and ischaemic cortical necrosis with high mortality. Injection of Glu-plasminogen (Glu-Plg) showed a dose-dependent attenuation of thrombotic angiopathy, GFR loss, and ischaemic necrosis in mice with CC embolism. Intermediate dose of Glu-Plg had transient protective effect, while high dose provided full protection without bleeding complications.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Biochemistry & Molecular Biology
Carolina Conte, Giulia Antonelli, Maria Elena Melica, Mirko Tarocchi, Paola Romagnani, Anna Julie Peired
Summary: Chronic kidney disease (CKD) is a global health burden affecting over 840 million people worldwide. It presents sex disparities in its pathophysiology, epidemiology, clinical manifestations, and disease progression. While CKD is more frequent in females, males have a higher risk of progressing to end-stage kidney disease. Recent studies have highlighted the role of sex hormones in the development and progression of CKD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Transplantation
Paola Romagnani, A. Richard Kitching, Nelson Leung, Hans-Joachim Anders
Summary: Glomerulonephritis (GN) is a diverse group of immune-mediated disorders, which cannot be properly classified or treated based on histological patterns alone. To overcome this problem, a new classification system is proposed that considers disease category, immunological activity, and chronicity, which will guide the therapeutic approach.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Biochemistry & Molecular Biology
Marco Allinovi, Francesco Sessa, Gianluca Villa, Andrea Cocci, Samantha Innocenti, Maria Zanazzi, Lorenzo Tofani, Laura Paparella, Dritan Curi, Calogero Lino Cirami, Riccardo Campi, Andrea Mari, Agostino Ognibene, Maria Lorubbio, Alessandra Fanelli, Stefano Romagnoli, Paola Romagnani, Andrea Minervini
Summary: The study aimed to identify and compare serum and urinary predictors for predicting long-term decline in glomerular filtration rate (GFR) after robotic Nephron-Spearing Surgery (rNSS). The results showed that patients who developed clinical acute kidney injury (AKI) had a more pronounced decline in eGFR at 24 months. KineticGFR at 4 hours and NephroCheck at 10 hours were found to be efficient predictors of post-operative AKI and long-term eGFR decline. Combining these biomarkers could help identify high-risk patients as early as 10 hours after surgery.
Article
Urology & Nephrology
Zhihui Zhu, Karoline A. T. Rosenkranz, Yoshihiro Kusunoki, Chenyu Li, Martin Klaus, Oliver Gross, Maria-Lucia Angelotti, Giulia Antonelli, Luigi Cirillo, Paola Romagnani, Nassim Bouteldja, Alireza Vafaei Sadr, Roman D. Buelow, Peter Boor, Hans-Joachim Anders
Summary: A preclinical study in mice suggests that triple blockade of RAS/SGLT2/MR may significantly improve renal outcomes in Alport syndrome and other progressive CKDs due to synergistic effects on the glomerular and tubulointerstitial compartments.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
